Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Company profile
Ticker
ANIX
Exchange
Website
CEO
Amit Kumar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
COPYTELE INC, ITUS Corp
SEC CIK
Corporate docs
Subsidiaries
Anixa Diagnostics Corporation • Certainty Therapeutics, Inc. • CopyTele International Ltd. • CopyTele Marketing Inc. • ITUS Patent Acquisition Corporation • J-Channel Industries Corporation • Loyalty Conversion Systems Corporation • Secure Web Conference Corporation • Encrypted Cellular Communications Corporation • Auction Acceleration Corp. ...
IRS number
112622630
ANIX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
16 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
10 Mar 23
DEF 14A
Definitive proxy
27 Jan 23
S-8
Registration of securities for employees
4 Jan 23
10-K
2022 FY
Annual report
4 Jan 23
8-K
Regulation FD Disclosure
8 Dec 22
8-K
Regulation FD Disclosure
29 Sep 22
EFFECT
Notice of effectiveness
20 Sep 22
CORRESP
Correspondence with SEC
15 Sep 22
UPLOAD
Letter from SEC
14 Sep 22
Latest ownership filings
Financial summary
| Quarter (USD) | Jan 23 | Oct 22 | Jul 22 | Apr 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Oct 22 | Oct 21 | Oct 20 | Oct 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 9.79 mm | 9.79 mm | 9.79 mm | 9.79 mm | 9.79 mm | 9.79 mm |
| Cash burn (monthly) | 856.67 k | 1.67 mm | 852.00 k | 1.05 mm | 662.67 k | 606.92 k |
| Cash used (since last report) | 1.65 mm | 3.21 mm | 1.64 mm | 2.02 mm | 1.28 mm | 1.17 mm |
| Cash remaining | 8.14 mm | 6.58 mm | 8.15 mm | 7.77 mm | 8.51 mm | 8.62 mm |
| Runway (months of cash) | 9.5 | 3.9 | 9.6 | 7.4 | 12.8 | 14.2 |
Institutional ownership, Q4 2022
11.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 46 |
| Opened positions | 13 |
| Closed positions | 2 |
| Increased positions | 11 |
| Reduced positions | 9 |
| 13F shares | Current |
|---|---|
| Total value | 13.55 bn |
| Total shares | 3.63 mm |
| Total puts | 5.90 k |
| Total calls | 26.70 k |
| Total put/call ratio | 0.2 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 1.31 mm | $5.56 bn |
| UBS UBS Group AG - Registered Shares | 622.54 k | $2.65 bn |
| BLK Blackrock | 294.22 k | $1.25 bn |
| Geode Capital Management | 274.29 k | $1.17 mm |
| Long Focus Capital Management | 165.70 k | $704.23 mm |
| STT State Street | 102.10 k | $433.93 mm |
| BK Bank Of New York Mellon | 97.62 k | $414.88 mm |
| Susquehanna International | 71.02 k | $301.85 mm |
| NTRS Northern Trust | 58.52 k | $248.69 mm |
| Raymond James & Associates | 57.22 k | $243.17 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Jan 23 | Baskies Arnold M | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.19 | 25,000 | 104.75 k | 25,000 |
| 3 Jan 23 | Kumar Amit | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.19 | 700,000 | 2.93 mm | 700,000 |
| 3 Jan 23 | Titterton Lewis H jr | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.19 | 25,000 | 104.75 k | 25,000 |
| 3 Jan 23 | Catelani Michael | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.19 | 350,000 | 1.47 mm | 350,000 |
| 3 Jan 23 | Emily Gottschalk | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.19 | 25,000 | 104.75 k | 25,000 |
News
HC Wainwright & Co. Maintains Buy on Anixa Biosciences, Raises Price Target to $12
23 Mar 23
Chardan Capital Maintains Buy on Anixa Biosciences, Raises Price Target to $9
22 Mar 23
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $11 Price Target
28 Feb 23
12 Health Care Stocks Moving In Thursday's After-Market Session
23 Feb 23
Press releases
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting
27 Mar 23
Anixa Biosciences Reassures Shareholders It Has No Accounts at Silicon Valley Bank
13 Mar 23
Anixa Biosciences to Provide Corporate Update at its 2023 Annual Meeting of Stockholders
2 Mar 23
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology
27 Feb 23
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
21 Feb 23